痰热清注射液联合哌拉西林舒巴坦钠治疗肺部感染的临床效果  

Clinical Efficacy of Tanreqing Injection and Piperacillin and Sulbactam Sodium in the Treatment of Pulmonary Infections

作　　者：翟正英 李晓培 蔡芸[3] ZHAI Zheng-ying;LI Xiao-pei;CAI Yun(Department of General Internal Medicine,Henan(Zhengzhou)Zhonghui Cardiovascular Hospital,Zhengzhou 450000,Henan Province,China;Department of Geriatrics,Zhonghui Cardiovascular Hospital,Henan(Zhengzhou),Zhengzhou 450000,Henan Province,China;Drug Clinical Research Office,Department of Pharmacy,Medical Security Center,General Hospital of the Chinese People's Liberation Army Postal,Beijing 100080,China)

机构地区：[1]河南(郑州)中汇心血管病医院普通内科,河南郑州450000 [2]河南(郑州)中汇心血管病医院老年医学科,河南郑州450000 [3]中国人民解放军总医院医疗保障中心药剂科药物临床研究室,北京100080

出　　处：《罕少疾病杂志》2025年第4期53-55,共3页Journal of Rare and Uncommon Diseases

基　　金：国家自然科学基金(81770004)。

摘　　要：目的探讨痰热清注射液与哌拉西林舒巴坦钠联合治疗肺部感染的临床效果。方法选取河南(郑州)中汇心血管病医院2021年4月至2024年4月收治的共计180例肺部感染患者,以随机数字表法分成研究组(n=90,痰热清注射液联合哌拉西林舒巴坦钠)和对照组(n=90,哌拉西林舒巴坦钠),比较两组临床疗效、中医证候积分、肺功能、炎症因子、不良反应。结果研究组治疗总有效率高于对照组(P<0.05);两组治疗后中医证候积分下降(P<0.05),研究组低于对照组(P<0.05);两组治疗后第1秒用力呼气容积(FEV1)、最大自主分钟通气量(MVV)升高(P<0.05),研究组高于对照组(P<0.05);两组治疗后C反应蛋白(CRP)、降钙素原(PCT)、白细胞介素-17(IL-17)下降(P<0.05),研究组低于对照组(P<0.05);两组不良反应发生率比较差异无统计学意义(P>0.05)。结论肺部感染患者采用痰热清注射液联合哌拉西林舒巴坦钠治疗,能够促进临床疗效提高,缓解症状、恢复肺功能,使炎症因子水平降低,且不会导致不良反应增加。Objective To explore the clinical efficacy of Tanreqing injection and piperacillin and sulbactam sodium in the treatment of patients with pulmonary infections.Methods A total of 180 pulmonary infection patients from April 2021 to April 2024 who were admitted to henan(Zhengzhou)Zhonghui Cardiovascular Hospital were selected,and divided into the study group(n=90,Tanreqing injection solution and piperacillin sulbactam sodium)and the control group(n=90,piperacillin sulbactam sodium)according to different treatment methods.The clinical efficacy,TCM syndrome score,lung function,inflammatory factors,and adverse reactions were compared in both groups.Results In the treatment total effective rate,in comparison of the control group,the study group was higher(P<0.05).After treatment,the TCM syndrome scores in both groups were decreased(P<0.05),and in comparison of the control group,the study group was lower(P<0.05).After treatment,the forced expiratory volume in one second(FEV1)and maximum voluntary minute ventilation(MVV)in both groups were increased(P<0.05),and in comparison of the control group,the study group was higher(P<0.05).After treatment,the C-reactive protein(CRP),procalcitonin(PCT),and interleukin-17(IL-17)levels in both groups were decreased(P<0.05),and in comparison of the control group,the study group was lower(P<0.05).Both groups were no significant differences in the incidence of adverse reactions(P>0.05).Conclusion The treatment of pulmonary infection patients with Tanreqing injection and piperacillin sulbactam sodium can effectively improve clinical efficacy,relieve symptoms,help patients recover lung function,promote the reduction of inflammatory factor levels,and will not lead to an increase in adverse reactions.

关 键 词：痰热清注射液 派拉西林舒巴坦钠 肺部感染 临床效果 

分 类 号：R816.41[医药卫生—放射医学]